FDA Brief

Warning letters Drugs

FDA warning letter to

Kaylaan LLC

High riskIssued Aug 19, 2024Posted Sep 3, 2024Division of Pharmaceutical Quality Operations I

FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.

What happened

FDA inspected Kaylaan’s drug manufacturing facility in Floral Park, NY, from February 14 to March 1, 2024. The investigator found the firm had distributed batches of Kaylaan Toothpaste Tablets with Fluoride since 2021 without finished-product release testing for identity and strength, without identity testing of incoming sodium fluoride, and without an adequate quality unit, process validation, cleaning validation, or maintained facility. FDA reviewed the firm’s March 21, 2024 response and found it inadequate.

What FDA found

  1. Kaylaan released batches of fluoride toothpaste tablets without testing each batch for identity and strength of the active ingredient.

    21 CFR 211.165(a)
  2. Kaylaan did not test incoming raw materials, including sodium fluoride, to confirm identity and relied on supplier certificates without validating them.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. Kaylaan lacked an adequate quality unit with written procedures, training, stability testing, annual product reviews, and complete batch records.

    21 CFR 211.22(a) and 211.22(d)
  4. Kaylaan did not validate its manufacturing processes and changed the formula without adequate change control; inspectors saw chipped and sticking tablets.

    21 CFR 211.100(a)
  5. Kaylaan had no cleaning validation studies, cleaning procedures, or cleaning logs for drug manufacturing equipment.

    21 CFR 211.67(b)
  6. The facility was not in good repair: peeling paint, cracked taped windows, and white powder on vents and light fixtures above tablet presses.

    21 CFR 211.58

What FDA wants

FDA tells Kaylaan to correct the violations promptly and respond in writing within 15 working days with corrective actions, testing plans, retrospective assessments, and a schedule for completion if work is not finished. FDA also recommends engaging a qualified CGMP consultant before continuing drug manufacturing and distribution.

Who should pay attention

  • retailers and distributors selling Kaylaan toothpaste tablets
  • brands that rely on supplier certificates of analysis for active ingredients
  • contract manufacturers and labs serving OTC drug firms

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk